Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Operating Expenses (2023 - 2025)

Immunome (IMNM) has disclosed Operating Expenses for 3 consecutive years, with $72.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 14.99% year-over-year to $72.9 million, compared with a TTM value of $231.1 million through Dec 2025, down 26.61%, and an annual FY2025 reading of $231.1 million, down 26.61% over the prior year.
  • Operating Expenses was $72.9 million for Q4 2025 at Immunome, up from $60.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $133.3 million in Q1 2024 and bottomed at $6.8 million in Q1 2023.
  • Average Operating Expenses over 3 years is $55.8 million, with a median of $52.0 million recorded in 2024.
  • The sharpest move saw Operating Expenses soared 1850.67% in 2024, then plummeted 64.33% in 2025.
  • Year by year, Operating Expenses stood at $98.5 million in 2023, then fell by 12.97% to $85.7 million in 2024, then fell by 14.99% to $72.9 million in 2025.
  • Business Quant data shows Operating Expenses for IMNM at $72.9 million in Q4 2025, $60.1 million in Q3 2025, and $50.5 million in Q2 2025.